Inify Laboratories – Extended subscription period

STOCKHOLM – May 30th, 2022 Inify Laboratories AB has decided to extend the Subscription Period in the ongoing Subsequent Offering to 3 June 2022 at 16:30 hours (CEST). As a consequence of this extension, the payment date will be on or about 8 June 2022 and delivery of shares will take place on or about […]
Read More

Inify Laboratories – extra bolagsstämma 2022-05-09

STOCKHOLM – 9 maj 2022 Inify Laboratories har hållit en extra bolagsstämma den 9 maj 2022. Bifogat finns en sammanfattning av de beslut som fattades vid den extra bolagsstämman. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Sammanfattning Extra bolagsstämma 2022-05-09 (pdf)
Read More

Inify Laboratories – kallelse till extra bolagsstämma

STOCKHOLM – 11 april 2022 Inify Laboratories bjuder härmed in sina aktieägare till en extra bolagsstämma den 9 maj 2022. Bifogat finns kallelse inklusive dagordning och information om hur man registrerar sig och röstar. Vänligen kontakta: för frågor angående den extra stämman. Nedladdningar Kallelse extra bolagsstämma (pdf) Anmälningsblankett bolagsstämma (pdf) Styrelsens redogörelse enligt 13 […]
Read More

INIFY Laboratories AB becomes an independent company

STOCKHOLM – December 10, 2021 – ContextVision, a medical technology software company specializing in image processing, today announces that at the EGM of ContextVision on Dec 10th, it was resolved that the subsidiary INIFY Laboratories will become an independent company through a distribution of its shares to existing shareholders of ContextVision. The company will build […]
Read More

In the Pan-European multicenter clinical study FirstPath, INIFY Prostate produced highly accurate, robust and homogenous results at all sites

STOCKHOLM – August 31, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that results from FirstPath – a European multicenter clinical study evaluating performance of INIFY® Prostate in routine clinical practice – were presented at the European Congress of Pathology by […]
Read More